ZoeNCure Therapeutics raises Rs 20 crore (USD 2.4M) in seed round led by Tyagi Family to advance cancer therapies toward clinical trials.
PRIVATEOct 04, 2026
Amount Raised
₹200 Million
Round Type
Seed
BiotechnologyHealth CareTherapeutics
Investors
Manoj TyagiShyambir TyagiTyagi Family
Description
ZoeNCure Therapeutics, a Delhi-based oncology biotechnology startup, has closed a Rs 20 crore seed funding round led by the Tyagi Family, high-net-worth individuals based in Gurugram. The round includes participation from angel co-investors and brings the company's total equity raised to Rs 22.5 crore. The capital will advance ZoeNCure's lead antibody drug conjugate candidate toward first-in-human Phase 1 clinical studies for liver and gastrointestinal cancers. This marks the second investment from the Tyagi Family, who previously contributed Rs 2.5 crore in pre-seed funding.
Company Information
Company
ZoeNCure Therapeutics Pvt. Ltd
About
ZoeNCure Therapeutics is an oncology biotechnology company focused on developing high-potency targeted cancer therapies. The company specializes in next-generation Antibody Drug Conjugate (ADC) programs with dual-payload precision oncology therapies designed to overcome treatment resistance. ZoeNCure is advancing its lead ADC candidate toward Phase 1 clinical studies for severe liver and gastrointestinal cancers, particularly hepatocellular carcinoma (HCC).
Fundz sees it the moment ZoeNCure Therapeutics Pvt. Ltd raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
